+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bevacizumab"

From
From
From
Ovarian Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Ovarian Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 250 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 277 Pages
  • Global
From
From
Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Peritoneal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Peritoneal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Bevacizumab - Biosimilar Insight, 2025 - Product Thumbnail Image

Bevacizumab - Biosimilar Insight, 2025

  • Report
  • April 2025
  • 80 Pages
  • Global
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Lung Cancer Therapeutics Market 2025-2033 - Product Thumbnail Image

Lung Cancer Therapeutics Market 2025-2033

  • Report
  • March 2025
  • 140 Pages
  • Global
From
From
Ovarian Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Ovarian Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
From
Hepatic Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Vestibular Schwannoma - Pipeline Insight, 2025 - Product Thumbnail Image

Vestibular Schwannoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Loading Indicator

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs. Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated. Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more